SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (219)9/15/1998 2:35:00 PM
From: scaram(o)uche  Read Replies (1) of 579
 
OK, excerpts.......

from the section "Corporate Collaborations", describing the BMY program in Alzheimer's/beta amyloid..... "We expect to see a compound in clinical development in the near future."

from the section "Corporate Collaborations", describing the Novartis program...... "Novartis has initiated development of drug candidates for epilepsy. That agreement is scheduled to expire at the end of September, but SIBIA will have continuing rights to the development projects and sole rights to any new discoveries in this field." [It is worth remembering that the current efforts with VGCC/pain once belonged to Lilly]

from the section "Corporate Collaborations", describing Lilly's efforts...... "Lilly continues in pre-clinical studies to develop a lead compound from our prior collaboration for stroke."

[to be continued]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News